We are live on
!
Find out more
AG
Aperio Group Portfolio holdings
AUM
$33.8B
1-Year Est. Return
31.46%
This Fund
S&P 500
This Quarter
Est. Return
+1.96%
1 Year Est. Return
+31.46%
3 Year Est. Return
+70.41%
5 Year Est. Return
+146.02%
10 Year Est. Return
–
AUM
$25.3B
AUM Growth
+$814M
(+3.3%)
Cap. Flow
+$613M
Cap. Flow
% of AUM
2.42%
Top 10 Holdings %
Top 10 Hldgs %
16.08%
Holding
3,081
New
5
Increased
1,358
Reduced
932
Closed
769
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$31.9M |
| 2 |
Apple
AAPL
|
+$24.9M |
| 3 |
AT&T
T
|
+$21.1M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$20.2M |
| 5 |
Biogen
BIIB
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$34M |
| 2 |
RHT
Red Hat Inc
RHT
|
+$22.2M |
| 3 |
HSBC
HSBC
|
+$20.3M |
| 4 |
APC
Anadarko Petroleum
APC
|
+$19.9M |
| 5 |
CAJ
Canon, Inc.
CAJ
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.05% |
| 2 | Financials | 16.76% |
| 3 | Healthcare | 12.56% |
| 4 | Consumer Discretionary | 10.05% |
| 5 | Communication Services | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CISN
2101
DELISTED
Cision Ltd. Ordinary Share
CISN
| $243K | ﹤0.01% |
31,554
+30,579
| +3,136% | +$263K |
|
|
GBT
2102
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $242K | ﹤0.01% |
4,988
-517
| -9% | -$26.9K |
|
2103
Sea Limited
SE
$65.4B
| $241K | ﹤0.01% |
7,784
-2,080
| -21% | -$69.8K |
|
|
PEI
2104
DELISTED
Pennsylvania Real Estate Investment Trust
PEI
| $241K | ﹤0.01% |
2,806
-2,134
| -43% | -$181K |
|
|
RESI
2105
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $241K | ﹤0.01% |
20,876
-759
| -4% | -$8.78K |
|
2106
Extreme Networks
EXTR
$3.94B
| $240K | ﹤0.01% |
33,020
+1,902
| +6% | +$13.8K |
|
|
AAMI
2107
Acadian Asset Management
AAMI
$3.08B
| $240K | ﹤0.01% |
24,256
+14,787
| +156% | +$150K |
|
2108
Stride
LRN
$3.41B
| $239K | ﹤0.01% |
9,059
-3,938
| -30% | -$113K |
|
2109
Mueller Industries
MLI
$14.7B
| $239K | ﹤0.01% |
33,336
+656
| +2% | +$4.6K |
|
|
SASR
2110
DELISTED
Sandy Spring Bancorp Inc
SASR
| $239K | ﹤0.01% |
7,101
+230
| +3% | +$7.97K |
|
|
CLDR
2111
DELISTED
Cloudera, Inc.
CLDR
| $239K | ﹤0.01% |
26,995
+10,492
| +64% | +$72.9K |
|
|
AKRX
2112
DELISTED
Akorn Inc
AKRX
| $239K | ﹤0.01% |
63,015
-25,334
| -29% | -$90.5K |
|
2113
NRC Health Common Stock
NRC
$432M
| $238K | ﹤0.01% |
4,117
+1,056
| +34% | +$65.4K |
|
2114
Standard Motor Products
SMP
$851M
| $238K | ﹤0.01% |
4,898
+1,795
| +58% | +$82.2K |
|
2115
Sturm, Ruger & Co
RGR
$594M
| $237K | ﹤0.01% |
5,680
-6,936
| -55% | -$324K |
|
2116
Ethan Allen Interiors
ETD
$570M
| $235K | ﹤0.01% |
12,301
-44,556
| -78% | -$848K |
|
2117
argenx
ARGX
$53.4B
| $234K | ﹤0.01% |
2,052
-375
| -15% | -$50.7K |
|
2118
BancFirst
BANF
$3.79B
| $234K | ﹤0.01% |
4,227
-935
| -18% | -$51.9K |
|
2119
Gorman-Rupp
GRC
$2.14B
| $234K | ﹤0.01% |
6,723
+1,029
| +18% | +$32.7K |
|
2120
Helios Technologies
HLIO
$2.57B
| $234K | ﹤0.01% |
5,764
+80
| +1% | +$3.48K |
|
|
VIVO
2121
DELISTED
Meridian Bioscience Inc
VIVO
| $234K | ﹤0.01% |
24,595
-10,004
| -29% | -$105K |
|
|
ENDP
2122
DELISTED
Endo International plc
ENDP
| $234K | ﹤0.01% |
72,971
+14,380
| +25% | +$46.4K |
|
|
TDAY
2123
USA Today Co
TDAY
$1.27B
| $233K | ﹤0.01% |
26,465
-6,939
| -21% | -$63.3K |
|
2124
TriCo Bancshares
TCBK
$1.84B
| $233K | ﹤0.01% |
6,418
+309
| +5% | +$11.3K |
|
2125
AZZ Inc
AZZ
$4.35B
| $232K | ﹤0.01% |
5,318
-864
| -14% | -$37.8K |
|
Similar funds
OU
CTA
GAM
CCI
SWM
LCM
HCMNY
BII
Aperio Group's Q3 2019 Portfolio in Review
As of Q3 2019, Aperio Group held 3,081 positions worth $25.3B, up 3.3% from $24.5B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Aperio Group's Q3 2019 filing shows 5 new, 1,358 increased, 932 reduced and 769 closed positions. Its largest new stake was Genmab: 211,272 shares worth $4.28M. The largest sale was Pfizer, an estimated $34M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- Aperio Group's largest Q3 2019 buy was Genmab: 211,272 shares worth $4.28M.
- Aperio Group added most to Microsoft in Q3 2019, an estimated $31.9M increase.
- Aperio Group's biggest Q3 2019 reduction was Pfizer, cutting an estimated $34M.
- Aperio Group fully exited Red Hat Inc in Q3 2019, selling an estimated $22.2M.
- Aperio Group's ten largest holdings make up 16% of its $25.3B portfolio in Q3 2019.
- Aperio Group opened 5 new positions and closed 769 in Q3 2019.
- Aperio Group's portfolio value rose 3.3% quarter-over-quarter to $25.3B.
Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.